The Defense Threat Reduction Agency awarded a definitive contract to Vitrivax, Inc. for optimization and production of single-shot vaccines for melioidosis and glanders on January 12, 2023, with a ceiling value of $29.8 million under cost-plus-fixed-fee pricing and no set-aside.
Place of performance is Boulder, Colorado. The originating solicitation was a Broad Agency Announcement posted November 2, 2016, seeking innovative research and development projects focused on countering weapons of mass destruction across six technology areas at Technology Readiness Levels 2 through 6. Performance was to occur within the United States over a potential six-year timeframe through October 2021, with selected awards eligible for extension up to five years. Ultimate completion date is January 11, 2028.